Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrer's perspective

Nuclear Medicine Communications

Volumn 23, Issue 11, 2002, Pages 1041-1046

  Gopalan, D ^a   Griffiths, D ^a   Townsend, C ^a   Prvulovich, E ^a   Bomanji, J ^a   Costa, D C ^a   Ell, P J ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Fluorodeoxyglucose; Oncology; Positron emission tomography; Referrer

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; BISMUTH DERIVATIVE; GERMANIUM DERIVATIVE; METAL OXIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CHILD; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DECISION MAKING; DISEASE MANAGEMENT; EPIDEMIOLOGY; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NEOPLASM; ONCOLOGY; PATHOLOGY; PATIENT REFERRAL; PROSPECTIVE STUDY; STATISTICS; UNITED KINGDOM; UTILIZATION REVIEW; CANCER DIAGNOSIS; COLON CANCER; CYCLOTRON; HODGKIN DISEASE; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MEDICAL AUDIT; PARANEOPLASTIC SYNDROME; PHYSICIAN ATTITUDE; POSITRON EMISSION TOMOGRAPHY; WHOLE BODY SCANNER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATTITUDE OF HEALTH PERSONNEL; CHILD; DECISION MAKING; DISEASE MANAGEMENT; FEMALE; FLUORODEOXYGLUCOSE F18; GREAT BRITAIN; HEALTH CARE SURVEYS; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REFERRAL AND CONSULTATION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036854526     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200211000-00002     Document Type: Article

References (9)

1. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncology 2001; 3: 157-164.
2. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: (S1-S93).
3. O'Doherty MJ, Marsden PK. Being equipped for clinical PET. Lancet 2001; 356: 1701-1703.
4. Position paper on a strategy for the provision of PET in the UK. Intercollegiate Standing Committee on Nuclear Medicine. 2002; (in press).
5. Brix G, Nosske D, Glatting G, Minkov V, Reske SV. Results of a nationwide survey of PET examinations in Germany in 1999: radiopharmaceuticals, frequency of applications and effective doses. Eur J Nucl Med 2002; 29: 1091-1097.
6. Tucker R, Coel M, Ko J, Morris P, Druger G, McGuigan P. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical centre. J Clin Oncol 2001; 19: 2504-2508.
7. Van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS, multicentre randomised trial. Lancet 2002; 359: 1388-1393.
8. 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 2001; 42: 1334-1347.
9. 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med 2001; 42: 586-590.